JP4750278B2 - 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 - Google Patents

新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 Download PDF

Info

Publication number
JP4750278B2
JP4750278B2 JP2000591989A JP2000591989A JP4750278B2 JP 4750278 B2 JP4750278 B2 JP 4750278B2 JP 2000591989 A JP2000591989 A JP 2000591989A JP 2000591989 A JP2000591989 A JP 2000591989A JP 4750278 B2 JP4750278 B2 JP 4750278B2
Authority
JP
Japan
Prior art keywords
bretylium
anion
pharmaceutically acceptable
cation
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000591989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534379A5 (enExample
JP2002534379A (ja
Inventor
マービン・ビー・バケイナー
モーリス・エム・クリーボイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maurice M Kreevoy
Original Assignee
Maurice M Kreevoy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maurice M Kreevoy filed Critical Maurice M Kreevoy
Publication of JP2002534379A publication Critical patent/JP2002534379A/ja
Publication of JP2002534379A5 publication Critical patent/JP2002534379A5/ja
Application granted granted Critical
Publication of JP4750278B2 publication Critical patent/JP4750278B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000591989A 1999-01-08 2000-01-06 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 Expired - Fee Related JP4750278B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11514399P 1999-01-08 1999-01-08
US60/115,143 1999-01-08
US11656799P 1999-01-21 1999-01-21
US60/116,567 1999-01-21
PCT/US2000/000350 WO2000040232A2 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Publications (3)

Publication Number Publication Date
JP2002534379A JP2002534379A (ja) 2002-10-15
JP2002534379A5 JP2002534379A5 (enExample) 2010-06-03
JP4750278B2 true JP4750278B2 (ja) 2011-08-17

Family

ID=26812887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000591989A Expired - Fee Related JP4750278B2 (ja) 1999-01-08 2000-01-06 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用

Country Status (10)

Country Link
US (1) US6482811B1 (enExample)
EP (1) EP1140054B1 (enExample)
JP (1) JP4750278B2 (enExample)
AT (1) ATE290857T1 (enExample)
AU (1) AU781996B2 (enExample)
CA (1) CA2358459C (enExample)
DE (1) DE60018704T2 (enExample)
IL (2) IL144199A0 (enExample)
MX (1) MXPA01007024A (enExample)
WO (1) WO2000040232A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
KR20080017489A (ko) 2005-07-22 2008-02-26 더 프록터 앤드 갬블 캄파니 약물 유발성 부정맥 발생률 감소용 조성물
JP4750499B2 (ja) * 2005-08-01 2011-08-17 日華化学株式会社 イオン性液体並びにそれを用いた抗菌剤及び抗菌性繊維
EP2953627A4 (en) * 2013-02-07 2017-03-29 Research Foundation Of The City University Of New York NSAIDs DERIVATIVES AND USES THEREOF
CA2998875C (en) 2015-09-17 2023-08-29 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
EP4117660B1 (en) * 2020-03-11 2025-11-05 Ohio State Innovation Foundation Methods of modulating t-cell activation and treating chronic heart failure using carboranes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036106A (en) * 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US3911125A (en) * 1973-05-23 1975-10-07 Marvin B Bacaner Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction
US4147768A (en) 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
JPH01500589A (ja) * 1986-03-21 1989-03-01 ユーラシアム　ラボラトリーズ　インコーポレーテツド 薬剤組成物
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JP3355593B2 (ja) 1994-08-19 2002-12-09 信越化学工業株式会社 固形腸溶製剤の製造方法
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
JP3149122B2 (ja) 1994-11-07 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5980951A (en) 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036106A (en) * 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system

Also Published As

Publication number Publication date
EP1140054B1 (en) 2005-03-16
ATE290857T1 (de) 2005-04-15
AU781996B2 (en) 2005-06-23
CA2358459A1 (en) 2000-07-13
EP1140054A2 (en) 2001-10-10
US6482811B1 (en) 2002-11-19
DE60018704D1 (de) 2005-04-21
DE60018704T2 (de) 2006-05-04
IL144199A (en) 2006-10-05
CA2358459C (en) 2011-05-24
WO2000040232A3 (en) 2000-11-23
IL144199A0 (en) 2002-05-23
JP2002534379A (ja) 2002-10-15
AU2602300A (en) 2000-07-24
WO2000040232A2 (en) 2000-07-13
MXPA01007024A (es) 2002-03-27

Similar Documents

Publication Publication Date Title
US6884792B2 (en) Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
JP4750278B2 (ja) 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用
AU739275B2 (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
EP2300001A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
TW201521786A (zh) 胺碘酮類似物（ｂｕｄｉｏｄａｒｏｎｅ）調配物
AU2014231724B2 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
MX2007008845A (es) Metodos para control del intervalo qt.
EP2303259A1 (en) Dronedarone for the prevention of cardioversion
JPH0142246B2 (enExample)
US5604199A (en) Method of treating fibrosis in skeletal muscle tissue
JP2698865B2 (ja) 筋緊張性ジストロフィー症治療剤
WO1999040919A1 (en) Remedies for cardiac dilastolic disorders
EP0968715B1 (en) Loratadine for use as an antiarrhymthmic
JP2769217B2 (ja) 心臓状態の処置のためのプロパフェノン及びキニジンの持効性組成物
JP4032437B2 (ja) 痴呆治療剤
Murphy Drug profile: Synadrin
WO2005011690A1 (en) Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
WO2005025674A1 (de) Kombination von phenylcarbonsäureamiden mit beta-adrenozeptoren-blockern und deren verwendung zur behandlung von vorhofarrhythmien
JPS6011422A (ja) 抗筋ジストロフイ−症剤
KR20240051234A (ko) 심장질환용제 및 심장질환의 개선 방법
WO2006053037A2 (en) A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
ZA200105931B (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions.
WO2009071405A1 (en) Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
HK1220609B (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
JPH11511725A (ja) 炭酸塩／重炭酸塩で緩衝したジクロロ酢酸を含む組成物と、代謝異常および心血管障害の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100317

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100317

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110328

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110519

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140527

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees